President Obama Reopens Debate On Patented Biologics: Will the FDA Quickly Define an Abbreviated Pathway for Biosimilars?

類似資料

• New FDA Guidance on Off-Label Promotion Falls Short for Everyone: Obama Administration Is Likely to Revisit It
  著者:: Barlas, Stephen
  出版事項: (2009)
• FDA Pleases No One With Final Guidance On Naming of Biologicals and Biosimilars
  著者:: Barlas, Stephen
  出版事項: (2017)
• New Challenges to the FDA’s Drug-Labeling Policy: Democrats Are Poised to Pounce
  著者:: Barlas, Stephen
  出版事項: (2008)
• Senate May Compromise on ‘Biosimilars’: But Length of Market Exclusivity Poses a Stumbling Block
  著者:: Barlas, Stephen
  出版事項: (2008)
• FDA Science Base Badly Eroded: But Will Congress Provide Urgent New Funding?
  著者:: Barlas, Stephen
  出版事項: (2008)